Latest Humanized antibody Stories
Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease.
BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc.
INCLINE VILLAGE, Nev., Aug. 11 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
BOSTON, July 1 /PRNewswire/ -- China PharmaHub Corp. ("PharmaHub"), announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc.
MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr.
INCLINE VILLAGE, Nev., May 4 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P.
NEW YORK, March 24 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc.
EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies â€“ the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.
INCLINE VILLAGE, Nev., March 16 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on April 15, 2010.
INCLINE VILLAGE, Nev., March 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P.
- A political dynamiter.